Share on StockTwits

Analysts at Canaccord Genuity began coverage on shares of Vital Therapies (NYSE:VTL) in a research report issued to clients and investors on Monday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $20.00 price target on the stock. Canaccord Genuity’s price objective suggests a potential upside of 61.55% from the stock’s previous close.

Several other analysts have also recently commented on the stock. Analysts at William Blair initiated coverage on shares of Vital Therapies in a research note on Monday, May 12th. They set an “outperform” rating and a $28.00 price target on the stock. Analysts at Credit Suisse initiated coverage on shares of Vital Therapies in a research note on Monday, May 12th. They set an “outperform” rating and a $16.00 price target on the stock.

Vital Therapies (NYSE:VTL) opened at 12.38 on Monday. Vital Therapies has a one year low of $10.66 and a one year high of $13.00. The stock’s 50-day moving average is $12.30 and its 200-day moving average is $12.30. The company’s market cap is $261.4 million.

Vital Therapies, Inc is a biotherapeutic company. The Company focused on developing a cell-based therapy targeting the treatment of all forms of acute liver failure.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.